Steric and electronic parameters of 4'-substituents play significant roles in steering the conformation of nucleoside analogues. In order to investigate the relationship of 4'-group with antiviral enhancement, novel 4'-hydroxymethyl-5'-norcarbocyclic adenosine phosphonic acid analogues were designed and synthesized from 2,2-dimethyl-1,3-dioxolane-4-ethanol (5) using reiterative Grignard addition and ring-closing metathesis (RCM) as key reactions. The synthesized adenosine phosphonic acids analogues (22) and (23) were subjected to antiviral screening against HIV-1. Compound (23) exhibited moderate anti-HIV activity (EC50 = 8.61 μM) in the CEM cell line.
Introduction
The resistance of glycoside bond to enzymatic hydrolysis catalyzed by nucleoside phosphorylase 1 is one of the critical points in nucleoside antiviral chemotherapy. In order to avoid such enzymatic degradation as well as to improve the antiviral activity, a great number of structural modifications have been carried out on both the sugar and the heterocycle moiety of nucleosides. One strategy has been to replace the oxygen of the furanose ring by a methylene group, which gives rise to carbocyclic nucleosides. 2 Although these two classes of rings are far from being identical, the cyclopentene or cyclopentane ring allows carbocyclic nucleosides to be recognized as substrates or inhibitors of various enzymes. 3 Recently, 4'-homologated nucleosides such as 4'-fluoromethyl-2'-deoxycytidine (1) 4 and 4'-hydroxymethylthymidine (2) 5 analogues are molecules of considerable interest ( Figure 1 ). One of reasons for this prominence arises from the notable biological activities as anti-HIV agents. Modeling studies demonstrated the presence of a narrow, relatively hydrophobic 4'-pocket that can accommodate these substitutions, contributing to the observed enhancement in potency. 6 More recently, 4'-branched-5'-norcarbocyclic phosphonic acid analogues, such as 4'-vinyl-cpAP (3) and 4'-ethynyl-cpAP (4) 6 have encouraged the search for novel nucleosides as potential anti-HIV agents among this class of compounds ( Figure 1 ). 7 The phosphonate has certain advantages over its phosphate counterpart as it is metabolically stable because its phosphoruscarbon bond is not susceptible to hydrolytic cleavage. 8 The spacial location of the oxygen atom, namely the β-position from the phosphorus atom in the nucleoside analogue, plays a critical role in the antiviral activity. This increased antiviral activity with this oxygen atom may be attributed to the increased binding capacity of the phosphonate analogues to target enzymes. 9 Moreover, a phosphonate nucleoside analogue can skip the requisite first phosphorylation, which is a crucial step for the activation of nucleosides. This is frequently a limiting event in the phosphorylation sequence, which ultimately leads to triphosphates. 10 Actually, the exact role of the substituents in 4'-position of nucleoside analogues has not been fully explored. In continuation of our effort to find more efficient therapeutic agents against HIV and to provide analogues for probing the conformational preferences of enzymes associated with the metabolism of nucleosides and nucleotides, we have designed and prepared a novel class of nucleosides comprising 4'-hydroxymethyl-5'-norcarbocyclic phosphonic acid analogues.
As depicted in Scheme 1, the target compounds were prepared from commercially available 2,2-dimethyl-1,3-dioxolane-4-ethanol, (5). The hydroxyl functional group of (5) was subjected to protection reaction by benzyl bromide (BnBr, NaH, DMF) to furnish the acetonide (6), which was subjected to hydrolysis to provide diol derivative (7). The selective protection of primary hydroxyl group of (7) was successfully accomplished under mild silylation conditions (TBDMSCl, imidazole) to give the secondary alcohol (8) . 11 The secondary hydroxyl group of (8) was oxidized to the ketone (9) using Corey and Kim's oxidation conditions (NCS, DMS). 12 The corresponding ketone functional group of (9) was subjected to an addition re- action by vinylmagnesium bromide to give the tertiary hydroxyl analogue (10), which was again silylated (TBDMSOTf, 2.6-lutidine) 13 to give the protected compound (11) . Removal of the benzyl protecting group of (11) under dissolving metal reduction 14 for a prolonged time (ca 25 min) furnished the desired alcohol (12) , which was oxidized to the aldehyde (13) using Swern oxidation conditions 15 (DMSO, oxalyl chloride, TEA). The aldehyde (13) was again subjected to nucleophilic Grignard conditions 16 by vinylmagnesium bromide to yield divinyl (14) , which was subjected to ring-closing metathesis (RCM) conditions using 2nd generation Grubbs catalyst (C46H65Cl2N2PRu) 17 to provide cyclopentenol (15a) (35%) and (15b) (36%), which were readily separated by silica gel column chromatography. The nuclear Overhauser enhancement (NOE) experiments with cyclopentenols (15a) and (15b) confirmed these assignments. As expected, NOE enhancements were found between the cis-oriented hydrogens. Upon irradiation of C1-H, weak NOE patterns were observed at the proximal hydrogens of compound (15b) [C 4 -CH-(0.78%)] compared with those of compound (15a) [C 4 -CH-(1.21%)] (Figure 2) .
Initially, to synthesize the desired 5'-norcarbocyclic adenosine nucleoside analogues, the protected cyclopentenol (15b) was treated with 6-chloropurine under Mitsunobu coupling conditions 18 (DIAD and PPh3). However, the reaction produced a very low yield and was not reproducible. Alternatively, to couple the 6-chloropurine to cyclopentenol derivative (15a) using well known palladium(0)-catalysis, 19 hydroxyl group of (15a) was transformed to the allylic formate analogue (16) using ethyl chloroformate. Compound (16) was coupled with the nucleosidic base anions generated by NaH/DMSO using a catalyst [tris(dibenzylidene-acetone)-dipalladium(0)-chloroform] adduct to provide the 5'-norcarbocyclic nucleoside analogues (17) (Scheme 2). 20 Sequential double desilylation of (17) and selective monosilylation of corresponding diol (18) produced the 5'-norcarbocyclic nucleoside analogue (19) , which was treated with diethylphosphonomethyl triflate 21 using lithium t-butoxide to yield the nucleoside phosphonate analogue (20). The chlorine group of (20) was then converted to amine with methanolic ammonia at 70 o C to give the corresponding adenine phosphonate derivative (21) . 4 Desilylation of silicon protection group followed by hydrolysis of diethyl phosphonate functional groups of (22) gave the adenosine phosphonic acid derivative (23).
The synthesized nucleoside phosphonate and phosphonic acid analogues (22) and (23) were then evaluated for antiviral activity against human immunodeficiency virus. The procedures for measuring the antiviral activity toward wild-type HIV and cytotoxicity have been reported previously. 22 As shown in Table 1 , nucleoside phosphonic acid (23) exhibited significantly more anti-HIV activity than its parent nucleoside diethyl phosphonate (22) at concentrations up to 100 μM. Further develop- ment toward optimal prodrugs will likely allow efficient delivery of the phosphonate to the lymphatic system and provide a novel nucleotide RT inhibitor for the treatment of HIV.
In summary, based on the potent anti-HIV activity of 4'-branched nucleoside and 5'-norcarbocyclic nucleoside analogues, we have designed and successfully synthesized novel 4'-hydroxymethyl-5'-norcarbocyclic nucleoside analogues starting from 2,2-dimethyl-1,3-dioxolane-4-ethanol. 4'-Vinyl analogue (3) and ethynyl analogue (4) were found to inhibit RT with an IC 50 =0.67 μM, and 0.15 μM, respectively. 6 Taking these data into account, the proposed 4'-pocket in the active site of RT is sensitive to steric and electronic changes in the 4'-substituent, especially when this involves increasing the van der Waals radius or possibly changes in the projection angle of the 4'-substituent into the pocket. Compounds 22 and 23 exhibited weak anti-HIV activity, indicating that the hydrophilic pocket such as hydroxymethyl group at 4'-position of 5'-norcarbocyclic nucleosides system makes the conformation to be unfavorable for interaction with enzymes associated with the kinases of nucleosides and nucleotides.
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. The elemental analyses were performed using a Perkin-Elmer 2400 analyzer (PerkinElmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out under an atmosphere of nitrogen unless otherwise specified. Dry dichloromethane, benzene and pyridine were obtained by distillation from CaH2. Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
(±)-4-(2-Benzyloxyethyl)-2,2-dimethyl-1,3-dioxolane (6). To a suspension of NaH (60% in mineral oil, 495 mg, 12.45 mmol) in THF (50 mL) was slowly added a solution of alcohol 5 (1.52 g, 10.39 mmol) in THF (50 mL). Benzyl bromide (1.95 g, 11.43 mmol) in THF (50 mL) was added to the mixture at 0 o C and stirred overnight at rt. The reaction was quenched by water (10 mL) and further diluted with water (150 mL). The mixture was extracted with EtOAc (2 × 150 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:20) to give 6 (2.23 g, 91%) as a colorless oil. (±)-4-Benzyloxy-butane-1,2-diol (7). To a solution of 6 (120 mg, 0.508 mmol) dissolved in MeOH (10 mL), con. HCl (1 mL) was added. The mixture was stirred at rt for 12 h and neutralized with TEA. The mixture was concentrated in vacuo and the residue was dissolved in H 2 O (50 mL). The mixture was extracted with EtOAc (3 × 50 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 2:1) to give 7 (80 mg, 81%) as a colorless oil. (
±)-4-Benzyloxy-1-(t-butyldimethylsilanyloxy)-butan-2-ol (8).
To a stirred solution of diol 7 (2.2 g, 11.25 mmol) and imidazole (1.14 g, 16.87 mmol) in CH2Cl2 (80 mL), t-butyldimethylsilyl chloride (1.86 g, 12.37 mmol) was slowly added at -10 o C. The mixture was stirred at 0 o C for 2 h, and further stirred for 3 h at rt. The mixture was quenched by adding a NaHCO 3 solution (5 mL) and further diluted with water (100 mL). The mixture was extracted using CH 2 Cl 2 (150 mL), dried over MgSO4, filtered and then concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:10) to give compound 8 (2.72 g, 78%) as a colorless syrup: C. Saturated NH4Cl solution (5 mL) was added to the mixture, which was slowly warmed to room temperature. The mixture was diluted with water (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:12) to give 10 (1.32 g, 81%) as a colorless oil: (
±)-[3-(t-Butyldimethylsilanyloxy)-3-(t-butyldimethylsilanyloxymethyl)-pent-4-enyloxymethyl]-benzene (11).
To a cooled, stirred solution of tertiary alcohol 10 (242 mg, 0.72 mmol) and 2,6-lutidine (0.6 mL, 6.14 mmol) in dry methylene chloride (12 mL) was added t-butyldimethylsilyl trifluoromethane sulfonate (TBDMSOTf, 0.9 mL, 3.07 mmol). The reaction mixture was warmed to room temperature, and stirred for 3 h at the same temperature. The mixture was quenched by saturated sodium bicarbonate (5 mL) and water (80 mL) was added. The mixture was extracted with ethyl acetate (80 mL), washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:25) to give 11 (282 mg, 87%) as a colorless oil: (
±)-3-(t-Butyldimethylsilanyloxy)-3-(t-butyldimethylsilanyloxymethyl)-pent-4-en-1-ol (12).
Anhydrous ammonia (approximately 12 mL) was condensed into a flask containing a solution of benzyl ether 11 (246 mg, 0.546 mmol) in dry tetrahydrofuran (4 mL) at -78 o C. To this mixture was added a piece of metallic lithium sufficient to maintain a blue color, and the resulting deep blue solution was stirred at -78 o C for 3 min. Methanol was added dropwise at the same temperature until the blue color disappeared. The colorless solution was stirred for 30 min at -78 o C, and then solid ammonium chloride (ca. 3.5 g) was added. After stirring for 1 h at -78 o C, the ammonia was allowed to evaporate. Diethyl ether (40 mL) was added, and the mixture was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:10) to give 12 (163 mg, 83%) as a colorless oil: (
rel)-(3R and 3S,5S)-5-(t-Butyldimethylsilanyloxy)-5-(tbutyldimethylsilanyloxymethyl)-hepta-1,6-dien-3-ol (14)
. Divinyl analogue 14 was synthesized as a diastereomeric mixture from aldehyde 13 by a procedure similar to that described for 10: yield 74%; (
rel)-(1R,4S)-4-(t-Butyldimethylsilanyloxy)-4-(t-butyldimethylsilanyloxymethyl)-cyclopent-2-enol (15a) and (rel)-(1S,4S)-4-(t-butyldimethylsilanyloxy)-4-(t-butyldimethylsilanyloxy-methyl)-cyclopent-2-enol (15b).
To a solution of 14 (417 mg, 1.08 mmol) in dry methylene chloride (10 mL) was added 2nd generation Grubbs catalyst (48.0 mg, 0.0565 mmol). The reaction mixture was refluxed overnight and cooled to rt. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:10) to give cyclopentenol 15a (135 mg, 35%) and 15b (139 mg, 36%). The reaction mixture was then quenched using a saturated NaHCO 3 solution (0.5 mL) and evaporated under reduced pressure. The residue was partitioned between water and ethyl acetate and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layer extracts were washed with brine, dried over MgSO 4 and filtered. The organic solvent was evaporated in vacuo and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:13) to give 16 (695 mg, 69%) as a colorless syrup. 
Data of 15a:

